Kornimate/medical-research-clean huggingface dataset:
platelet-rich plasma (prp) for treatment of symptomatic lumbar facet syndrome of the spine

Conditions: Platelet-Rich Plasma

Summary: the purpose of this study is to investigate the feasibility of standardized autologous platelet rich plasma injections into osteoarthritic lumbar facet joints to treat back pain and improve patient function.


Eligibility criteria:
inclusion criteria: * suspicion of z-joint mediated low back pain * pain rating of ≥4/10 on a vas scale * symptom duration of 3 or more months * failed conservative therapy (minimum of pt and pain medications) * have diagnosis of lumbar facet syndrome after mri, x-ray, or ct imaging of any severity and a medial branch block with local anesthetic that confirms lumbar facet pathology. exclusion criteria: * inability to undergo fluoroscopically guided procedures * current pregnancy * prior spinal surgery with hardware * intolerance to local anesthesia, contrast medium, or blood derivatives * local or systemic infection or spinal infection * irreversible coagulopathy * patients that require strict anticoagulation and cannot be off antiplatelet medication for at least a week * less than 18 years of age * corticosteroid shot within last 3 months into affected lumbar facet joint because of concern of damage to cartilage in the joint in that time period. * patients with workman compensation related back pain * patients with rheumatic cause of lumbar facet arthritis. * patients who have had a radiofrequency neurotomy of the nerves innervating their affected facet joints within the last year
multiparametric characterization of colorectal cancers (metrad)

Conditions: Colo-rectal Cancer

Summary: the primary goal of this observational study is to assess the predictive value of a model developed through a multiparametric analysis of clinical images, histopathological data, ct scans, and molecular analysis. this analysis will be conducted on a retrospective cohort recruited at chu brest (training group). the model will then be validated using external cohorts from other centers (test group).

around 20% of patients with colorectal cancer present with synchronous liver metastases at the time of diagnosis. in recent years, there has been increasing interest in the high-throughput extraction of quantitative data from medical images, a technique known as radiomics. radiomic analysis can involve both qualitative and quantitative imaging parameters, which may be used independently or integrated into multiparametric prediction models. this is a multicenter, retrospective study designed to investigate the demographic, clinical, and radiological features, treatment regimens, and outcomes of patients diagnosed with colorectal cancer. the study will involve the collection of anonymized clinical data, including age, sex, diagnosis date, treatment details, results from histopathological and genetic analyses, as well as pre- and post-treatment medical imaging typically performed as part of the management of colorectal cancer patients, along with survival and tumor recurrence data. primary evaluation criteria prediction of recurrence/treatment response based on the radiomic model. secondary evaluation criteria the impact of ct scan image acquisition and reconstruction parameters on the prognostic model.

Eligibility criteria:
inclusion criteria: patients who have undergone surgery for colorectal cancer. exclusion criteria: * patients under legal protection (guardianship, curatorship, etc.) * refusal to participate (expressed opposition) * individuals with conditions that could interfere with the study protocol or impact data integrity

Keywords: colon cancer rectal cancer radiomics
prognostic study of via dynamic change of dt-dna in drainage fluid after radical prostatectomy

Conditions: Prostatic Neoplasms; ctDNA

Summary: this study investigates the prognostic value of dynamic changes in drainage tumor dna(dt-dna) levels found in the peritoneal drainage fluid after radical prostatectomy. prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. while psa levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of dt-dna levels in the prognosis of prostate cancer. the findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.

this study examines the prognostic significance of dt-dna levels in the peritoneal drainage fluid following radical prostatectomy, a common surgical treatment for prostate cancer. psa is widely used as a biomarker for prostate cancer diagnosis, treatment response, and recurrence monitoring in the blood. however, this research seeks to explore the prognostic value of dt-dna in the drainage fluid. the study involves continuous monitoring of dt-dna levels in the drainage fluid after radical prostatectomy, with the hypothesis that dynamic changes in these levels could serve as an early warning system for potential tumor recurrence, residual disease, or metastasis. the research will correlate these fluid dt-dna levels with patient outcomes, recurrence rates, and other clinical factors to determine their predictive value. by investigating this novel source of dt-dna monitoring, the study aims to reduce invasive tests, enhance post-operative surveillance, and improve early detection of disease recurrence for prostate cancer patients. this research could contribute to refining post-surgical care protocols, offering a new tool for predict long-term outcomes for individuals undergoing radical prostatectomy.

Eligibility criteria:
inclusion criteria: * prostate cancer patients treated with radical prostatectomy exclusion criteria: * 1. received neoadjuvant endocrine/chemotherapy before surgery; * 2. urine leakage after surgery (positive creatinine test of drainage fluid).
a prospective randomized trial comparing partial hepatectomy and tace plus pei for small hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: presently,the diagnostic method of small hepatocellular carcinoma has been greatly elevated in china.the treatment is being from simplification to diversification,from entirety to individualization.confronting small hepatocellular carcinoma,we not select simple operation treatment but select a treatment that have more predominance and more fitting with patients in various kinds of treatment methods;including operation ,tace,pei,et al.which is better ? there are many arguments.

randomly put in group standard: 1. via clinical diagnosis and confirm it is primary liver cancer, and not accept any anticancer treatment. 2. age: 18-70 years. 3. early hepatocyte cancer，which is single focus of infection diameter ≤ 3 cm. 4. estimate tumor can gain treatment of curing operation or tace plus pei. 5. better liver function (child-pugh，class a or b). case loads: 160 residents with small hepatocellular carcinoma in china therapeutic regimen: under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. the operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. as for the micro-create treatment combination group, taking tace all through arteria cruralies super-elect arteria hepatica and injecting mito、fudr、iodipin. by b transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment. research end-point: 1. ensemble life span.to compare 1、2 and 3 year overall survival rate in hepatectomy and tace plus pei for small hepatocellular carcinoma 2. intraliver recurrence rate; distant metastasis rate; non-tumor life span; band tumor life span telephone call at any time

Eligibility criteria:
inclusion criteria: 1. via clinical diagnosis and confirm it is primary liver cancer, and not accept any anticancer treatment. 2. age:18-70years 3. early hepatocyte cancer，which is single focus of infection diameter ≤3cm. 4. estimate tumor can gain treatment of curing operation or micro-create treatment combineation 5. better liver function (child-pugh，class a or b) exclusion criteria: 1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. blood clotting function hindrance; 5. serious heart、lung、kidney disease.

Keywords: small hepatocellular carcinoma partial hepatectomy tace plus pei
ablation verses anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation

Conditions: Heart Failure; Recurrent Atrial Fibrillation

Summary: a streamlined af ablation procedure done without pv mapping as a daycase is more effective than anti-arrhythmic drugs at reducing all hospital episodes for recurrent atrial fibrillation.

avatar-af is a multicentre, randomised controlled study comparing a streamlined avatar-protocol ablation procedure to anti-arrhythmic therapy in patients with documented paroxysmal af who are considered to be failing current strategy for af. a secondary control arm will also compare the avatar-protocol to conventional af ablation. 300 patients who are on no prior anti-arrhythmic, 'pill-in-pocket' or taking regular anti-arrhythmics will be randomised in a 1:1:1 manner to a treatment strategy of either avatar-protocol ablation, anti-arrhythmic therapy or conventional af ablation and followed-up for 1 year.

Eligibility criteria:
inclusion criteria: 1. documented paroxysmal atrial fibrillation 2. modification or initiation of anti-arrhythmic agent required for symptom control 3. males or females eighteen (18) to eighty (80) years of age 4. suitable candidate for catheter ablation 5. signed informed consent exclusion criteria: 1. contraindication to catheter ablation 2. no carer to enable daycase discharge 3. arrhythmias other than af documented unless they have had curative ablation (eg. for atrial flutter) 4. no documentation of sinus rhythm within 3 months 5. valvular or coronary heart disease needing regular follow up 6. ef \<45% or moderate/severe lv dysfunction 7. active gastrointestinal disease 8. renal failure with creatinine \>200 μmol/l or on dialysis 9. active fever or infection 10. life expectancy shorter than the trial 11. allergy to contrast 12. severe cerebrovascular disease 13. bleeding or clotting disorders or inability to receive heparin 14. uncontrolled diabetes (hba1c ≥73 mmol/mol or hba1c ≤64 mmol/mol and fasting blood glucose ≥9.2 mmol/l) 15. serum potassium \[k+\] \ 5.0 mmol/l 16. malignancy needing surgery, chemotherapy or radiotherapy 17. pregnancy or women of child-bearing potential not using a highly effective method of contraception 18. must not have previous (4 weeks prior to screening) or current participation in another clinical trial with an investigational drug or investigational device 19. unable to give informed consent 20. uncontrolled thyroid disease defined as abnormal thyroid function tests causing cardiac manifestations within the last 6mths 21. unable to attend follow up visits

Keywords: heart failure
efficacy and safety of quetiapine compared with valproate in the treatment of patients with bipolar disorder and rapid cycling

Conditions: Bipolar Disorder

Summary: the purpose of the study is to evaluate the efficacy of quetiapine compared to valproate during a 12 month treatment period in subjects with bipolar disorder i or ii with rapid cycling.


Eligibility criteria:
inclusion criteria: * signed informed consent, men and women aged ³18 to £65 years with diagnosis of dsm-iv criteria for bipolar i or ii disorder, most recent episode manic, hypomanic, mixed or depressive with rapid cycling. exclusion criteria: * substance or alcohol dependence, female patients who are pregnant, lactating or at risk of pregnancy, diagnosis of schizophrenia or borderline personality disorder or antisocial personality disorder, history of seizure disorder, acute suicidal or external aggressive behaviour, legal incapacity or indication for treatment against the will of the patient by law.

Keywords: bipolar disorder i or ii with rapid cycling
intrauterine misoprostol versus intravenous oxytocin infusion during cesarean delivery

Conditions: Post Partum Hemorrhage

Summary: bleeding is still the major cause of mortality and morbidity in postpartum period. world health organization has reported 585000 deaths for pregnancy each year. twenty five percent of cases die from post-partum bleeding. mean amount of blood lost is 500 ml during normal vaginal delivery, 1000 ml in cesarean section, and 3500 ml during cesarean section with emergency hysterectomy


Eligibility criteria:
inclusion criteria: 1-uncomplicated pregnancy, 2-had no hypersensitivity or contraindications to prostaglandins. 3-had no history of coagulopathy. 4-accepting to participate in the study. exclusion criteria: \\1-women with anemia (haemoglobin \<8 gram ). 2 placental abnormality (e.g placenta previa,placenta abruption ) 3. history of complications at previous pregnancy especially postpartum hemorrhage. 4- maternal hypertension , current or previous history of heart disease ,liver ,renal disorders or known coagulopathy
randomized phase ii trial of anastrozole plus metronomic tegafur-uracil as neo-adjuvant therapy in postmenopausal breast cancer

Conditions: Breast Neoplasms

Summary: the aim of this study is to validate a treatment of anastrozole in combination with tegafur-uracil as pre-operative therapy for postmenopausal primary breast cancer. although pre-operative hormone therapy is a novel therapeutic approach, only hormone therapy has limitation in terms of efficacy. metronomic chemotherapy, which is the frequent administration of low-dose cytotoxic agents, is not only target tumor cells but also inhibiting angiogenesis. because there was a report that efficacy of hormone therapy add to metronomic chemotherapy as pre-operative therapy, a randomized phase ii trial of anastrozole (ana) in combination with/without metronomic tegafur-uracil (uft) as neo-adjuvant for postmenopausal breast cancer will be conducted.


Eligibility criteria:
inclusion criteria: * histologically-confirmed diagnosis of invasive breast cancer * clinical stage t2, n0 or n1, m0 (tnm classification) * patients must be postmenopausal * tumors are estrogen receptor (er) positive and human epidermal growth factor receptor (her2) negative * ecog performance status (ps) 0 or 1 * patients must be able to swallow tablets and capsules * candidates for mastectomy or breast-conserving surgery * adequate bone marrow, liver and renal function * written informed consent was obtained from all patients before randomization. exclusion criteria: * inoperable, bilateral or inflammatory breast cancer * multiple carcinoma * personal history of invasive carcinoma * patients receive systemic therapy of corticosteroid * patients receive estrogen preparation or raloxifene * patients with other concurrent severe and/or uncontrolled medical disease * patients whom doctors judged inadequate to the enrollment of this study by other reasons.
bym338 in chronic obstructive pulmonary disease (copd) patients with cachexia

Conditions: Chronic Obstructive Pulmonary Disease (COPD) With Cachexia

Summary: this study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of bym338 in patients with copd and cachexia. the primary outcome will be a change in thigh muscle volume compared to placebo. the study will last for approximately 24 weeks.


Eligibility criteria:
inclusion criteria: * written informed consent must be obtained before any assessment is performed. * males and females ages 40 to 80 years * smoking history of at least 10 pack-years * diagnosis of copd according to gold guidelines (gold, 2010), with a post-bronchodilator fev¬1 \< 80% predicted and fev1/fvc ratio \< 0.70 * bmi \<20 kg/m2 or skeletal muscle mass index by dxa \< 7.25 kg/m2 for men or \<5.45 kg/m2 for women. * in general stable health, including managed copd, by past medical history, physical examination, vital signs at baseline as determined by the investigator. exclusion criteria: * patients with mrc dyspnoea grade 5 (i.e. patients too breathless to leave the house or breathless when dressing) * plans for lung transplantation or lung reduction surgery within four months of enrollment * patients participating in a formal pulmonary rehabilitation program within 3 months of dosing * history of malignancy of any organ system (other than excised non-melanomatous carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. * diseases other than cancer known to cause cachexia or muscle atrophy, including but not limited to congestive heart failure of any stage, chronic kidney disease (estimated gfr \< 30 ml/min using the mdrd equation), rheumatoid arthritis, primary myopathy, stroke, hiv infection, tuberculosis or other chronic infection, uncontrolled diabetes mellitus, etc. * inflammatory bowel disease, celiac disease, short bowel syndrome, pancreatic insufficiency * use of any prescription drugs known to affect muscle mass, including androgen supplements, anti-androgens (such as lhrh agonists), anti-estrogens (tamoxifen, etc.) recombinant human growth hormone (rhgh), insulin, oral beta agonists, megestrol acetate, dronabinol, metformin, etc. * hemoglobin concentration below 11.0 g/dl at screening. * liver disease or liver injury. * use of other investigational drugs at the time of enrollment, or within 30 days and for any other limitation of participation in an investigational trial based on local regulations. * women of child-bearing potential. other protocol-defined inclusion/exclusion criteria may apply

Keywords: chronic obstructive pulmonary disease copd; cachexia; muscle wasting
a study of freeze-dried human protein c concentrate (tak-662) in participants with congenital protein c deficiency

Conditions: Protein C Deficiency

Summary: this study is conducted in japan of freeze-dried human protein c concentrate (tak-662) used to treat participants with congenital protein c deficiency. the main aim of the study is to evaluate for adverse events and effectiveness of congenital protein c deficiency (tak-662). during the study, participants with congenital protein c deficiency will be administered with tak-662 intravenous injection in under routine normal practice. the investigators will evaluate adverse events due to tak-662 for 12 months. for participants who will be administered in long-term supplementation of tak-662 after acute treatment or short-term supplementation, the investigator will evaluate for 24 months as a maximum. the study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.


Eligibility criteria:
inclusion criteria: - all participants with congenital protein c deficiency who are administered with freeze-dried human protein c concentrate (tak-662). exclusion criteria: - none

Keywords: ceprotin/protein c deficiency
med90 of ropivacaine for peripheral nerve block on posture-evoked pain in spinal anesthesia positioning

Conditions: Hip Fractures

Summary: this study aims to determine the minimum effective dose of ropivacaine for peripheral nerve block on posture-evoked pain for spinal anesthesia in elderly patients with hip fracture. three types of peripheral nerve block, including fascia iliaca block, femoral nerve block and pericapsular nerve group block (peng block) will be assessed.

patients with hip fractures are anticipated to endure sever pain caused by positional changes required for spinal anesthesia. providing analgesia before positioning not only increases patient comfort but also improves positioning and successful spinal block. peripheral nerve block is an effective strategy for relieving pain during postures change for spinal anesthesia in patients with hip fractures. three types of peripheral nerve block, including fascia iliaca block, femoral nerve block and pericapsular nerve group block (peng block), has been successfully used for analgesia for spinal anesthesia positioning in patients with hip fractures. however, the minimum effective dose of local anesthetics for these three types of peripheral nerve block is not known. this study aims to determine the minimum effective dose of ropovacaine in the three types of peripheral nerve block using a biased coin design up-and-down sequential method. successful block is defined as nrs score ≤3 by positional changes for spinal anesthesia, achieved at 20min after the block. med90 of ropivacaine for fascia iliaca block, femoral nerve block and peng block be assessed respectively. patients will receive ultrasound guided peripheral nerve block. the initial dose is chosen as 80 mg on the basis of clinical experience. subsequently, if a patient has an inadequate block, the ropivacaine dose is increased by 8 mg in the next subject. if a patient has a successful block, the next subject is randomized to receive either a lower dose (with a decrement of 8 mg), with a probability of b = 0.11, or the same dose, with a probability of 1 - b = 0.89. forty five successful blocks for each type of nerve block will be accomplished. med90 of each type of nerve block will be calculated by isotonic regression.

Eligibility criteria:
inclusion criteria: * age 65 - 85 years * american society of anesthesiologists physical statusⅰ- ⅲ * patients will receive hip replacement exclusion criteria: * patient refusal * cognitive impairment(nrs pain score cannot be assessed) * peripheral neuropathy * mutiple furacture * skin infection at the site of injection * allergy to ropivacaine、lidocaine or bupivacaine * contraindication to spinal anesthesia